<div id="readability-page-1"><article>New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients' doors LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit. The launch marks Niagen Bioscience's first direct-to-client access model and introduces at-home subcutaneous administration, eliminating the need for an in-person doctor’s or drug store visit, extending the reach of Niagen Plus beyond clinic visits.<div id="bwbodyimg"><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260504495993/en/2792928/4/NiagenPlus_At-Home_Injection_Kit_1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260504495993/en/2792928/4/NiagenPlus_At-Home_Injection_Kit_1.jpg"/>Niagen Bioscience launches Niagen Plus telehealth platform, unveiling Niagen At-Home Injection Kit offering</div>&#34;With this launch, we are expanding access to Niagen through a clinician-directed telehealth model designed around quality, convenience, and clinical oversight,&#34; said Rob Fried, Chief Executive Officer of Niagen Bioscience. &#34;We are introducing a new way for eligible patients to access pharmaceutical-grade Niagen from home while staying grounded in the scientific rigor, quality standards, and disciplined approach that define Niagen Bioscience.&#34;This clinician-directed telehealth program guides patients through an online medical intake and consultation with a licensed provider. Eligible patients may be prescribed the Niagen At-Home Injection Kit, a new prescription-only offering featuring Niagen, the most efficient, effective, high-quality NAD+ support for cellular health and overall vitality. If prescribed, the complete kit is dispensed by a licensed 503A pharmacy and shipped directly to the patient's door.In 2025, the U.S. injectable industry was valued at USD 223.6 billion, with sales projected to grow at approximately 6.8% CAGR through 2035, according to Future Market Insights. In the U.S., the longevity market is projected to grow from USD 9.16 billion in 2025 to USD 20.17 billion by 2035, a CAGR of 8.34%, according to SNS Insider.“What I find compelling here is the emphasis on process and quality,” said Dr. Chris Meletis, Former Dean and Chief Medical Officer of National College of Natural Medicine (NCNM) and advisor to Niagen Bioscience. “This is not a casual direct-to-consumer purchase. It is a clinician-directed telehealth program designed to evaluate eligibility and, when appropriate, provide prescription access to pharmaceutical-grade Niagen in an at-home format.”The Niagen At-Home Injection Kit is designed for subcutaneous administration and includes a sterile 500 mg vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, mixing syringe and needle for reconstitution, alcohol prep pads, and step-by-step instructions accessible by a QR code. The compounded kit is manufactured under cGMP standards using pharmaceutical-grade components and follows clinician-directed 50 mg or 100 mg dosing protocols, as prescribed.In a clinical safety trial, the Niagen At-Home Injection Kit was generally considered safe and well-tolerated, with no significant adverse effects reported at 50 mg/mL and 100 mg/mL dosages over the course of the study. By bypassing gut metabolism, injectable administration offers a more direct delivery pathway for Niagen, with preclinical models suggesting the potential for greater tissue availability.For additional information on our telehealth program and the Niagen At-Home Injection Kit, visit www.niagenplus.com.About Niagen Bioscience:Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)Forward Looking Statements:This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions.Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.<img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MDQ0OTU5OTNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MDQ0OTU5OTNyMQ"/>View source version on businesswire.com: https://www.businesswire.com/news/home/20260504495993/en/Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations &amp; Partnerships 310.405.5227 kendall.knysch@niagenbio.comNiagen Bioscience Investor Relations Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 Niagen@kcsa.comSource: Niagen Bioscience, Inc</article></div>

NAGE

Niagen Bioscience, Inc. (NASDAQ: NAGE) has launched a telehealth platform, Niagen Plus, offering a prescription-only Niagen At-Home Injection Kit for eligible U.S. patients. This innovative service allows patients to receive pharmaceutical-grade NAD+ support directly at home, eliminating the need for in-person visits. The kit includes all necessary components for subcutaneous administration and is designed to enhance cellular health. The telehealth program emphasizes quality and clinical oversight, ensuring safe and effective delivery of Niagen. The U.S. injectable market is projected to grow significantly, reflecting increasing demand for such health solutions.

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering | NAGE Stock News